Aytu Biopharma (AYTU) Equity Average (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Equity Average data on file, last reported at $24.7 million in Q1 2026.

• Equity Average for Q1 2026 came in at $24.7 million, down 24.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.7 million (down 24.85% YoY), and the FY2025 annual result was $23.3 million, down 30.4% from the prior year.
• Equity Average climbed to $24.7 million in Q1 2026 per AYTU's latest filing, from $18.7 million in the prior quarter.
• Over five years, Equity Average peaked at $83.3 million in Q1 2022 and troughed at $18.7 million in Q4 2025.
• A 5-year average of $36.8 million and a median of $32.5 million in 2023 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2025: Equity Average plunged 62.8% in 2022, then gained 3.2% in 2025.
• A 5-year view of Equity Average shows it stood at $47.1 million in 2022, then sank by 30.95% to $32.5 million in 2023, then retreated by 6.81% to $30.3 million in 2024, then slumped by 38.32% to $18.7 million in 2025, then jumped by 32.03% to $24.7 million in 2026.
• Business Quant data shows AYTU's Equity Average at $24.7 million in Q1 2026, $18.7 million in Q4 2025, and $21.1 million in Q3 2025.